Ridaforolimus

From Self-sufficiency
Jump to: navigation, search
Ridaforolimus
File:Deforolimus.svg
Systematic (IUPAC) name
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate
Identifiers
CAS Number 572924-54-0
ATC code none
PubChem CID 11520894
Chemical data
Formula C53H84NO14P
Molar mass Script error: No such module "math". g·mol−1
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ridaforolimus (also known as AP23573 and MK-8669; formerly known as Deforolimus[1]) is an immunosuppressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008, a phase III clinical trial of ridaforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients.[2][3]

On May 5, 2010, Ariad Pharmaceuticals and Merck & Company announced a clinical development and marketing agreement. With this agreement, Ariad will receive an upfront payment of $50 million with an additional $19 million reimbursement for R&D expenses incurred to date in the program. Future payments are triggered upon acceptance of the NDA by the FDA with another payment when the drug receives marketing approval. There are similar milestones for acceptance and approval in both Europe and Japan. Other milestone payments are tied to revenue goals for the drug.[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


  1. "ARIAD Reports First Quarter 2009 Development Progress and Financial Results- Ridaforolimus New USAN Name to Replace Deforolimus". ARIAD Pharmaceuticals. 2009. Retrieved 2009-05-07. 
  2. "SUCCEED: Landmark Global Phase 3 Trial Now Enrolling!". ARIAD Pharmaceuticals. 2008. Retrieved 2008-04-18. 
  3. Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study. ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.
  4. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1422441&highlight=